Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

offset our early stage expenses. As a result, we have ended the quarter at $3.6 million in cash and Certificates of Deposit vs. $3.7 million at April 30, 2008. Our revenue generation reduces our risk and provides a significant part of the capital required to grow high potential initiatives. We believe that this strategy gives us an advantage in this economic climate, while many in the biotech industry are more adversely affected by the financial crisis," stated Douglas Burkett, Ph.D., President of Champions Biotechnology, Inc. "Although our third quarter revenues of $1,052,175 were just slightly higher than our second quarter revenue of $1,044,172, the Company's deferred revenue in the third quarter climbed to $1,361,110 compared to $461,838 for our second quarter ended October 31, 2008.

"We intend to grow revenue from our Personalized Oncology and Preclinical eValuation businesses as we build our own drug pipeline," continued Dr. Burkett. "During the third quarter we identified oncology drug candidates from academic centers, pharmaceutical and biotech companies and began negotiations with license holders. We intend to leverage our predictive platform to screen drug candidates and acquire, or partner to develop, drug candidates that demonstrate efficacy in our Biomerk Tumorgraft models. The Company plans to partner with pharmaceutical or biotechnology companies to advance its drugs through remaining preclinical and clinical trials."

Highlights of the Company's third quarter ending January 31, 2009:

  1. The Company continued to expand its preclinical eValuation platform through additional collaborations to acquire tumor samples and by implanting, propagating and storing banks of Biomerk Tumorgrafts(TM) for use in future analysis of oncology drugs.
  2. The growing platform of Biomerk Tumorgrafts generated growing interest from large and small pharmaceutical and biotechnology compan
    '/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "DNA Sequencing ... offering. This report briefly reviews basics ... and their applications. Current large and small sequencers ... Various applications of sequencing are described including those ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... their offering. The markets for gene therapy ... approved gene therapy product and it is marketed in ... markets are estimated for the years 2014-2024. The estimates ...
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... Israel , September 2, 2015 ... TASE: BOLT) ("BioLight" or the "Company"), a firm ... in ophthalmology and cancer diagnostics, announced today that ... of glaucoma will be delivered at the Ophthalmology ... the European Society of Cataract & Refractive Surgeons ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... HAVEN, Conn., Sept. 9 Rib-X Pharmaceuticals, ... focused on the,discovery and development of novel ... today the formation of its,Clinical Advisory Board. ... will provide oversight and counsel on matters ...
... announces the,availability of MarketStats for agri-biotech equities ... offers a perspective on the,aforementioned equities and ... blogs and opinions., Investors can view ... division of FiSpace.net, a dynamic social networking ...
... Affitech AS, the Norwegian,antibody therapeutics company, today announced ... Chairman of its Board of Directors. The,Company,s previous ... of the,Board. Mr Broymer welcomed Dr McCullagh,s appointment ... McCullagh has agreed to take over from me ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 3SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG 2Affitech Appoints Dr. Keith McCullagh as Chairman 2Affitech Appoints Dr. Keith McCullagh as Chairman 3
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... mighty feat for a microscopic fungus built from threadlike ... several billion tons of nutrients out of the soil ... University-supported research on the movement of nitrogen brings into ... nearly all of Earth's food chains. , "Ignorance (about ...
... 22 biomarkers; results more accurate than PSA , Researchers ... identified a panel of 22 biomarkers that together provide ... current prostate specific antigen, or PSA, test. , The ... New England Journal of Medicine. , Researchers looked at ...
... through human genes has begun at the European ... within the MitoCheck consortium that includes 10 other ... all human genes, one-by-one, to find those involved ... questions of how cell division is regulated. , ...
Cached Biology News:Digging in the dirt for life's biochemical foundations 2U-M researchers identify new blood test for prostate cancer 2U-M researchers identify new blood test for prostate cancer 3Hunt for human genes involved in cell division under way 2